30-d #benznidazole is noninferior to standard 60-d tx (either benznidazole or nifurtimox) & had ⬇️drug side effects for #Chagas disease #TropMed #IDSky #TrypanosomaCruzi @thelancetinfdis.bsky.social
www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00436-6
www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00436-6
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
Benznidazole 150 mg once daily for 30 days showed non-inferior efficacy and the lowest
rate of drug-related adverse events among the regimens tested, supporting its adoption
as the preferred benznidaz...
www.thelancet.com
October 2, 2026 at 4:00 AM
30-d #benznidazole is noninferior to standard 60-d tx (either benznidazole or nifurtimox) & had ⬇️drug side effects for #Chagas disease #TropMed #IDSky #TrypanosomaCruzi @thelancetinfdis.bsky.social
www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00436-6
www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00436-6
brb making a triatomine bug piñata filled with nifurtimox and benznidazole
June 6, 2026 at 8:58 PM
brb making a triatomine bug piñata filled with nifurtimox and benznidazole
#TropMed24 Despite fact that Chagas predominantly acquired in childhood there were not paediatric friendly formulations. In collaboration with @dndi.bsky.social PedCHAGAS consortium helped develop paediatric friendly formulation of Benznidazole (2017) & subsequently also Nifurtimox (2020) 1/n
November 15, 2024 at 8:20 PM
#TropMed24 Despite fact that Chagas predominantly acquired in childhood there were not paediatric friendly formulations. In collaboration with @dndi.bsky.social PedCHAGAS consortium helped develop paediatric friendly formulation of Benznidazole (2017) & subsequently also Nifurtimox (2020) 1/n
#Benznidazole demonstrated a 94% parasitological negativization of #Chagas disease rate compared to posaconazole, which showed 95% parasitological failure.
Cardiac progression occurred in 5.5 % of participants after 3 to 10 years.
www.clinicalmicrobiologyandinfection.com/article/S119...
Cardiac progression occurred in 5.5 % of participants after 3 to 10 years.
www.clinicalmicrobiologyandinfection.com/article/S119...
Long-term follow-up of individuals with Chagas disease treated with posaconazole and benznidazole in a non-endemic region: the CHAGASAZOL cohort
The CHAGASAZOL trial compared posaconazole and benznidazole for treating chronic Chagas
Disease. Posaconazole showed poor short-term efficacy by means of qPCR compared to
benznidazole, but few studies...
www.clinicalmicrobiologyandinfection.com
April 17, 2025 at 5:12 AM
#Benznidazole demonstrated a 94% parasitological negativization of #Chagas disease rate compared to posaconazole, which showed 95% parasitological failure.
Cardiac progression occurred in 5.5 % of participants after 3 to 10 years.
www.clinicalmicrobiologyandinfection.com/article/S119...
Cardiac progression occurred in 5.5 % of participants after 3 to 10 years.
www.clinicalmicrobiologyandinfection.com/article/S119...
Congrats to Uniformed Services University Public Health PhD Candidate Josh Trowell for his newest publication- a systematic review & meta-analysis of therapies for indeterminate form Chagas Disease. It’s been a joy to serve as his thesis advisor
rdcu.be/eV5Np
rdcu.be/eV5Np
The efficacy and safety of benznidazole in adults with seropositive indeterminate form, Trypanosoma cruzi infection: a systematic review and meta-analysis
rdcu.be
December 24, 2025 at 2:37 AM
Congrats to Uniformed Services University Public Health PhD Candidate Josh Trowell for his newest publication- a systematic review & meta-analysis of therapies for indeterminate form Chagas Disease. It’s been a joy to serve as his thesis advisor
rdcu.be/eV5Np
rdcu.be/eV5Np
30-day benznidazole regimen matches standard efficacy with fewer side effects in Chagas disease trial.
30-day benznidazole regimen matches standard efficacy with fewer side effects in Chagas disease trial
30-day benznidazole regimen matches standard efficacy with fewer side effects in Chagas disease trial. Benznidazole 150 mg once daily for 30 days showed non-inferior efficacy and the lowest rate of drug-related adverse events among the regimens tested, supporting its adoption as the preferred benznidazole regimen for chronic Chagas disease; phase 3 trials of long-term efficacy across parasite genotypes and settings are required to support its incorporation into treatment guidelines. Randomised trial, Lancet Infectious diseases, 22 Sep 2026.
enclai.net
September 29, 2026 at 6:00 AM
30-day benznidazole regimen matches standard efficacy with fewer side effects in Chagas disease trial.
“The improved safety profile of the shorter benznidazole regimen, combined with once-daily dosing, has the potential to substantially increase the proportion of patients who complete treatment," medicalxpress.com/news/2026-09...
A shorter, better-tolerated treatment for Chagas disease is possible
A 30-day course of benznidazole taken once a day could offer people with chronic Trypanosoma cruzi infection a safer and more practical option than the current standard treatment, taken twice a day fo...
medicalxpress.com
October 1, 2026 at 1:50 PM
“The improved safety profile of the shorter benznidazole regimen, combined with once-daily dosing, has the potential to substantially increase the proportion of patients who complete treatment," medicalxpress.com/news/2026-09...
Development of benznidazole orally disintegrating tablets for paediatric patients pubmed.ncbi.nlm.nih.gov/40924016/
September 10, 2025 at 8:48 PM
Development of benznidazole orally disintegrating tablets for paediatric patients pubmed.ncbi.nlm.nih.gov/40924016/
Melt-Extruded Microparticles Based On Chitosan-pectin Complex for Delayed Dissolution of Benznidazole pubmed.ncbi.nlm.nih.gov/41345376/
December 5, 2025 at 8:15 AM
Melt-Extruded Microparticles Based On Chitosan-pectin Complex for Delayed Dissolution of Benznidazole pubmed.ncbi.nlm.nih.gov/41345376/
Pharmacological inhibition of Trypanosoma cruzi aldo-keto reductase (TcAKR) and its effect on benznidazole resistance pubmed.ncbi.nlm.nih.gov/41205370/
November 9, 2025 at 12:05 PM
Pharmacological inhibition of Trypanosoma cruzi aldo-keto reductase (TcAKR) and its effect on benznidazole resistance pubmed.ncbi.nlm.nih.gov/41205370/
#ScienceReadForSunday: Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic #Chagas disease (BENDITA) journals.plos.org/plosntds/art...
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)
Author summary Chagas Disease, caused by the parasite Trypanosoma cruzi, remains a major public health challenge, particularly in Latin America. Benznidazole and nifurtimox have been the standard…
journals.plos.org
October 12, 2025 at 9:15 AM
#ScienceReadForSunday: Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic #Chagas disease (BENDITA) journals.plos.org/plosntds/art...
Synthesis and Evaluation of a Hybrid Miltefosine-Silver Nanoparticle Complex: Synergistic Interaction with Benznidazole Against Trypanosoma cruzi pubmed.ncbi.nlm.nih.gov/40504446/
June 13, 2025 at 7:16 AM
Synthesis and Evaluation of a Hybrid Miltefosine-Silver Nanoparticle Complex: Synergistic Interaction with Benznidazole Against Trypanosoma cruzi pubmed.ncbi.nlm.nih.gov/40504446/
pubmed.ncbi.nlm.nih.gov/40318604/ another thing that higher planetary temperatures are bringing us
Efficacy of benznidazole delivery during Chagas disease nanotherapy is dependent on the nanocarrier morphology - PubMed
The causative agent of Chagas disease, the protozoan Trypanosoma cruzi, is an obligate intracellular parasite that is typically treated with daily oral administration of Benznidazole (BNZ), a parasiti...
pubmed.ncbi.nlm.nih.gov
September 18, 2025 at 11:37 PM
pubmed.ncbi.nlm.nih.gov/40318604/ another thing that higher planetary temperatures are bringing us
Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with Trypanosoma cruzi: comparative analysis with benznidazole pubmed.ncbi.nlm.nih.gov/42028916/
April 25, 2026 at 7:15 AM
Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with Trypanosoma cruzi: comparative analysis with benznidazole pubmed.ncbi.nlm.nih.gov/42028916/
Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with Trypanosoma cruzi: comparative analysis with benznidazole pubmed.ncbi.nlm.nih.gov/42028916/
April 26, 2026 at 4:37 AM
Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with Trypanosoma cruzi: comparative analysis with benznidazole pubmed.ncbi.nlm.nih.gov/42028916/
And we also tested combinations of these together with the current approved drug for #Chagas disease (Benznidazole)
Here are the synergy distribution maps:
• synergy = red
• antagonism = green
• additive = white
🧵 7
Here are the synergy distribution maps:
• synergy = red
• antagonism = green
• additive = white
🧵 7
January 16, 2026 at 3:50 PM
And we also tested combinations of these together with the current approved drug for #Chagas disease (Benznidazole)
Here are the synergy distribution maps:
• synergy = red
• antagonism = green
• additive = white
🧵 7
Here are the synergy distribution maps:
• synergy = red
• antagonism = green
• additive = white
🧵 7
A multicentre randomised, double-blind, double-dummy phase II clinical trial of benznidazole versus nifurtimox in adults with chronic Chagas disease in Brazil, alongside a prospective cohort: the BENBRASIL trial protocol pubmed.ncbi.nlm.nih.gov/42468958/
July 18, 2026 at 11:26 AM
A multicentre randomised, double-blind, double-dummy phase II clinical trial of benznidazole versus nifurtimox in adults with chronic Chagas disease in Brazil, alongside a prospective cohort: the BENBRASIL trial protocol pubmed.ncbi.nlm.nih.gov/42468958/
RRIDs were included in this Biomaterials paper. We value the author's support of reproducibility. #STMpublishing #OpenScience #accelerateopenscience
Efficacy of Benznidazole Delivery During Chagas Disease Nanotherapy is Dependent on the Nanocarrier Morphology
doi.org
May 21, 2025 at 7:01 AM
RRIDs were included in this Biomaterials paper. We value the author's support of reproducibility. #STMpublishing #OpenScience #accelerateopenscience
Recently, Brazil approved the registration of nifurtimox for pediatric use, complementing benznidazole in the treatment of people affected by #ChagasDisease at an early age.
👉 www.gov.br/anvisa/pt-br...
#BeatNTDs #NTDs #Chagas #DoençaDeChagas #GlobalHealth #NTDroadmap #Saúde #SaúdePública
👉 www.gov.br/anvisa/pt-br...
#BeatNTDs #NTDs #Chagas #DoençaDeChagas #GlobalHealth #NTDroadmap #Saúde #SaúdePública
August 4, 2026 at 3:24 PM
Recently, Brazil approved the registration of nifurtimox for pediatric use, complementing benznidazole in the treatment of people affected by #ChagasDisease at an early age.
👉 www.gov.br/anvisa/pt-br...
#BeatNTDs #NTDs #Chagas #DoençaDeChagas #GlobalHealth #NTDroadmap #Saúde #SaúdePública
👉 www.gov.br/anvisa/pt-br...
#BeatNTDs #NTDs #Chagas #DoençaDeChagas #GlobalHealth #NTDroadmap #Saúde #SaúdePública
With WORM HEAD'S medical advice, they're a self-correcting problem. Most MAGAts live in areas where CHAGAS disease is erupting. Wormy cut funding for monitoring, detection, public education, prevention, for research into cures. Currently, there's benznidazole nifurtimox, poorly tolerated long cycle.
cannot go lower. the magas will always support him no matter what.
October 4, 2025 at 3:38 PM
With WORM HEAD'S medical advice, they're a self-correcting problem. Most MAGAts live in areas where CHAGAS disease is erupting. Wormy cut funding for monitoring, detection, public education, prevention, for research into cures. Currently, there's benznidazole nifurtimox, poorly tolerated long cycle.
Millions live with Chagas disease, but treatment takes 8 weeks & has safety issues. NuestroBen, a new Phase III trial, will test if shorter regimens (2–4 weeks) can be equally effective but much safer, bringing hope for simpler care. doi.org/10.1136/bmjo.... ⤵️
New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III rando...
Introduction Chagas disease (CD) is one of the most neglected diseases in the world. In Latin America, CD is endemic in 21 countries, with an estimated 70 million people at risk of infection. Current ...
doi.org
October 1, 2025 at 8:14 AM
Millions live with Chagas disease, but treatment takes 8 weeks & has safety issues. NuestroBen, a new Phase III trial, will test if shorter regimens (2–4 weeks) can be equally effective but much safer, bringing hope for simpler care. doi.org/10.1136/bmjo.... ⤵️